Literature DB >> 8744024

The molecular basis for disease variability in cystic fibrosis.

B Kerem1, E Kerem.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The disease is characterized by a wide variability of clinical expression. The cloning of the CFTR gene and the identification of its mutations has promoted extensive research into the association between genotype and phenotype. Several studies showed that there are mutations, like the delta F508 (the most common mutation worldwide), which are associated with a severe phenotype and there are mutations associated with a milder phenotype. However, there is a substantial variability in disease expression among patients carrying the same mutation. This variability involves also the severity of lung disease. Furthermore, increased frequencies of mutations are found among patients with incomplete CF expression which includes male infertility due to congenital bilateral absence of the vas deferens. In vitro studies of the CFTR function suggested that different mutations cause different defects in protein production and function. The mechanisms by which mutations disrupt CFTR function are defective protein production, processing, channel regulation, and conductance. In addition, reduced levels of the normal CFTR mRNA are associated with the CF disease. These mutations are associated with a highly variable phenotype from healthy individuals or infertile males to a typical CF disease. This variability in disease expression is associated with different levels of normally spliced transcripts. Further understanding the mechanisms of CFTR dysfunction may suggest different therapeutic strategies for each class of mutations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8744024     DOI: 10.1159/000472174

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  19 in total

Review 1.  SNPing away at innate immunity.

Authors:  S J Chanock; C B Foster
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 2.  The cystic fibrosis transmembrane regulator gene and male infertility.

Authors:  C Quinzii; C Castellani
Journal:  J Endocrinol Invest       Date:  2000-11       Impact factor: 4.256

3.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

4.  P67L: a cystic fibrosis allele with mild effects found at high frequency in the Scottish population.

Authors:  A Gilfillan; J P Warner; J M Kirk; T Marshall; A Greening; L P Ho; T Hargreave; B Stack; D McIntyre; R Davidson; J C Dean; W Middleton; D J Brock
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

5.  CFTR gene mutations in men with bilateral ejaculatory-duct obstruction and anomalies of the seminal vesicles.

Authors:  D Meschede; B Dworniczak; H M Behre; S Kliesch; M Claustres; E Nieschlag; J Horst
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Homozygous Deletion of the CFTR Gene Caused by Interstitial Maternal Isodisomy in a Peruvian Child with Cystic Fibrosis.

Authors:  Flor Vásquez Sotomayor; Hugo Hernán Abarca-Barriga
Journal:  J Pediatr Genet       Date:  2019-02-13

Review 7.  Precision Genomic Medicine in Cystic Fibrosis.

Authors:  Eugene H Chang; Joseph Zabner
Journal:  Clin Transl Sci       Date:  2015-06-15       Impact factor: 4.689

8.  The molecular basis of partial penetrance of splicing mutations in cystic fibrosis.

Authors:  N Rave-Harel; E Kerem; M Nissim-Rafinia; I Madjar; R Goshen; A Augarten; A Rahat; A Hurwitz; A Darvasi; B Kerem
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

9.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

Review 10.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.

Authors:  Steven M Rowe; Frank Accurso; John P Clancy
Journal:  Proc Am Thorac Soc       Date:  2007-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.